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Abstract
Lipopolysaccharide (LPS) is responsible for many of the inflammatory responses and pathogenic effects of Gram-negative
bacteria, however, it also induces protective immune responses. LPS induces the production of inflammatory cytokines such
as TNF-a, IL-6, and IL-12 from dendritic cells (DCs) and macrophages. It is thought that IL-12 is required for one of the
protective immune responses induced by LPS, the T helper 1 (Th1)-immune response, which include the production of IFN-c
from Th1cells and IgG2c class switching. Here, we clearly demonstrate that intracellular delivery of LPS by LPS-formulated
liposomes (LPS-liposomes) does not induce the production of inflammatory cytokines from DCs, but enhances Th1-immune
responses via type-I IFNs, independent of IL-12. Collectively, our results strongly suggest that LPS-liposomes can effectively
induce Th1-immune responses without inducing unnecessary inflammation, and may be useful as an immune adjuvant to
induce protective immunity.
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Introduction
Lipopolysaccharide (LPS) is responsible for many of the
inflammatory responses and pathogenic effects of Gram-negative
bacteria. LPS recognition has been well studied, and Toll-like
receptor 4 (TLR4) is the best-characterized LPS sensor [1–6].
TLR4 signaling is also well studied, and it is known that 2 major
pathways, the MyD88-dependent and TRIF-dependent signaling
pathways, are activated when TLR4 recognizes LPS [4–7]. The
MyD88-dependent pathway is activated at the plasma membrane
and induces inflammatory responses such as the production of
TNF-a, IL-6, and IL-12 via activation of MAPK and NFkB in the
early phase. On the other hand, the TRIF-dependent pathway is
activated when LPS is taken into the cell [8,9]. Recently, in
support of this, Kagan et al. used endocytosis inhibitors and
showed that endocytosis of TLR4 with LPS initiates the TRIF-
dependent pathway in early endosomes [10]. TRIF-dependent
signaling induces the production of type-I IFN, which activates
anti-viral responses, and chemokines such as RANTES (also
known as CCL5) via activation of IRF-3 and NFkB in the late
phase [11].
IL-12 is involved in the differentiation of naive T cells into T
helper 1 (Th1) cells by heat-killed bacteria [12]. It has been
reported that IL-12p402/2 mice are defective in IFN-c produc-
tion and Th1-immune responses by LPS [13]. MyD882/2 mice
also have a profound defect in Th1-immune responses by LPS
[14]. Additionally, DCs from MyD882/2 mice are defective in the
production of IL-12 by LPS and induce IL-4–producing Th2 cells
but not IFN-c–producing Th1 cells [15]. Collectively, IL-12
production via the MyD88-dependent pathway is essential for the
Th1-immune responses induced by LPS. However, the MyD88-
dependent pathway also induces the production of inflammatory
cytokines such as TNF-a and IL-6 from immune cells, and this
cytokine production sometimes causes septic shock with cytokine
storm [16]. In contrast, it has recently been reported that TRIF-
biased TLR4 agonists can be used as vaccine adjuvants with low
toxicity [17]. TRIF-biased TLR4 agonist is a safe adjuvant,
however, its ability to induce immune responses is weaker than
that of LPS. Hence, adjuvants that defective in activation of
MyD88-dependent pathway will be safer, however, it is difficult to
induce effective and protective immune responses, such as IFN-c-
producing Th1 cells, Th1-immune responses [15,17].
In the present study, we newly prepared LPS-formulated
liposomes (LPS-liposomes) to activate only the TRIF-dependent
pathway via endocytosis [18]. In this study, we focused on the
effect of LPS-liposomes in DCs which is essential for inducing
adaptive immune responses. As expected, LPS-liposomes activated
the TRIF-dependent pathway, but not the MyD88-dependent
pathway, in DCs. IL-12 production was significantly decreased,
but IFN-b production was up-regulated by LPS-liposomes.
Surprisingly, LPS-liposomes enhanced Th1-immune responses
compared with LPS. We also found the induction of Th1-immune
responses by LPS-liposomes was depended on type-I IFNs, and
independent of IL-12. These results strongly suggest that LPS-
liposomes can effectively induce Th1-immune responses without
inducing unnecessary inflammation, and may be useful as an
immune adjuvant to induce protective immunity.
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Materials and Methods
Mice
Female C57BL/6 mice, purchased from Japan SLC (Shizuoka,
Japan), were used at 8–12 weeks of age. Wild-type C57BL/10ScSn
(WT), IL-12p35-defective C57BL/10 (IL-12p352/2), and IFN-a/
b receptor-defective C57BL/10 (IFN-a/bR2/2) mice were
obtained from the Max-Planck Institute for Immune biology and
Epigenetics (Freiburg, Germany). Female MyD88-defective
(MyD882/2) and TRIF-defective (TRIF2/2) mice were pur-
chased from Oriental Yeast co., ltd. (Tokyo, Japan). All mice were
housed in a specific pathogen-free environment at the Kitasato
University School of Science in strict accordance with the
Institutional Animal Care and Use Committee (IACUC) Guide-
lines. This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of Kitasato University School of Science.
The protocol was approved by the Committee on the Ethics of
Animal Experiments of Kitasato University School of Science
(Permit Number: SA1014). All efforts were made to minimize
suffering.
Reagents
Highly purified LPS from S. abortus equi was kindly provided by
Dr. Chris Galanos (Max-Planck Institute for Immune biology).
Anti-CD11c, anti-MHC-II, anti-CD40, anti-CD80, and anti-
CD86 antibodies for flow cytometry were purchased from BD
Pharmingen (San Diego, CA). Anti-IRF3, anti-phospho-IRF3
(Ser396), anti-IkBa and anti-GAPDH antibodies for immunoblot
analysis were purchased from Cell Signaling Technology (Tokyo,
Japan). AP-conjugated rabbit anti-mouse IgG1 antibody for
ELISA was purchased from Invitrogen. HRP-conjugated goat
anti-mouse IgG2c antibody for ELISA was purchased from
Thermo Scientific. 1,2-Dioleoyl-3-trimethylammonium-propane
(DOTAP) and 1,2-dipalmitoyl- sn-glycero-3-phosphoethanola-
mine-N-[methoxy (polyethylene glycol)-2000] (DPPE-PEG) were
obtained from Avanti Polar Lipids (Birmingham, AL). Ovalbumin
(OVA) was obtained from Sigma (Tokyo, Japan).
Generation of DCs
Bone marrow (BM)-derived DCs (BMDCs) were generated as
described previously [19]. Briefly, BM cells were obtained from
mice and cultured in RPMI 1640 containing 10% fetal calf serum
(FCS) and 10 ng/mL murine granulocyte macrophage colony-
stimulating factor (GM-CSF). Every 2 d, non-adherent cells were
Figure 1. Lipopolysaccharide (LPS)-liposomes induce interferon (IFN)-b production but not inflammatory cytokines in bone
marrow-derived dendritic cells (BMDCs). (A) BMDCs from wild-type (WT) mice (1.56105) were stimulated with LPS (100 ng/mL) or LPS-
liposomes (100 ng/mL) for 2 h (TNF-a) or 24 h (IL-6, IL-12p40, and RANTES). Cytokine levels were determined by ELISA. (B) BMDCs from wild-type
(WT) mice (1.56105) were stimulated with LPS (100 ng/mL) or LPS-liposomes (100 ng/mL) for 9 h. IFN-b levels were determined by ELISA. (C) BMDCs
(16106) from WT mice were stimulated with LPS or LPS-liposomes (10 or 100 ng/mL) for 4 h and expression of IFN-b and b-actin mRNAs was
determined by reverse transcription-polymerase chain reaction. PBS was control for LPS and liposomes was control for LPS-liposomes (Open
columns). Data in A and B are average of three independent experiments. The values represent means6 S.E.M *P,0.05 (LPS vs. LPS-liposomes). Data
shown in C is representative of three independent experiments.
doi:10.1371/journal.pone.0068671.g001
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discarded and the remaining cells were supplied with fresh
medium containing 10 ng/mL murine GM-CSF. At day 6, loosely
adherent cells were harvested by gentle pipetting and cultured for
a further 2 d. At day 8, the non-adherent cells were harvested.
Preparation of Liposomes
DOTAP was dissolved in chloroform, vacuum-desiccated, and
hydrated by vortexing with sterilized phosphate-buffered saline
(PBS) for liposomes, and LPS (10–100 mg/mL) in sterilized PBS
for LPS-liposomes, and diluted in PBS to obtain a final LPS
concentration of 1 mg/mL. LPS (1 mg/mL), LPS-lipoosmes (LPS
concentration of 1 mg/mL) and liposomes (same DOTAP
concentration of LPS-liposomes) was diluted in the medium were
used for the experiments. The size of LPS-liposome was
272.5665.3 nm (DLS-7000, Otsukaelectronics, Japan), and f-
potential was 8.561.8 (Laser Zee Model501, Pen Kem). For the
encapsulation of OVA, DOTAP and DPPE-PEG were dissolved
in chloroform, vacuum-desiccated, and hydrated by vortexing with
a mixture of LPS (1 mg/mL) and OVA (1 mg/mL) in PBS, and
diluted in PBS to obtain a final concentration of 100 mg/mL.
Following hydration, the dispersion was sonicated for 1 min in a
bath sonicator (Bioruptor, Cosmo Bio, Tokyo, Japan).
Cytokine Determination
BMDCs (1.56105) from WT mice were stimulated with LPS or
LPS-liposomes (100 ng/mL) for 2 h (TNF-a), 9 h (IFN-b) or 24 h
(IL-6, IL-12p40, and RANTES). BMDCs (1.06105) from
MyD882/2 and TRIF2/2 mice were stimulated with LPS or
LPS-liposomes (100 ng/mL) for 9 h (IFN-b) or 24 h (IL-12p40).
Cytokine levels were determined by ELISA. WT mice were
intravenously treated with LPS or LPS-liposomes (10 mg per
mouse). At 1.5 h after treatment, sera were harvested and the level
of TNF-ain the sera was determined by ELISA.
ELISA
TNF-a, IL-6, IL-12p40, IFN-c, and IL-4 were measured by
ELISA using OptEIA mouse cytokine detection kit (BD Biosci-
ences). IFN-b was measured by ELISA using mouse IFN-b ELISA
Kit (PBL interferon source). RANTES was measured by ELISA
using Quantikine mouse RANTES ELISA Kit (R&D Systems).
RT-PCR
BMDCs (16106) from WT mice were stimulated with LPS or LPS-
liposomes (10 or 100 ng/mL) for 4 h, and mRNA levels were
determined byRT-PCR. Total RNA (1 mg) was isolated using Isogen
solution (Nippon Gene, Toyama, Japan), as reported previously
[20,21]. cDNA was synthesized using SuperScript III. Then, cDNAs
were amplified with primers specific for IFN-b and b-actin.
Immunoblot Analysis
BMDCs (16106) from WT mice were stimulated with LPS or LPS-
liposomes (100 ng/mL) for0–120 min.Cells were lysedwith ice-cold
RIPA lysis buffer containing protease inhibitors, and the extracts
were subjected to immunoblot analysis. Immunoblot analysis was
performed using anti-IRF3, anti-phospho-IRF3 (Ser396), anti-IkBa
and anti-GAPDH antibodies, visualized with HRP conjugate
substrate system or an enhanced chemiluminescence detection
system. Band intensity was quantified with Image J 1.45.
Flow Cytometry
WT mice were intravenously treated with LPS or LPS-
liposomes (10 mg per mouse). At 6 h after treatment, splenocytes
were harvested and stained with PE-conjugated anti-CD11c,
FITC-conjugated anti-MHC-II and CD80, and biotin-conjugated
anti-CD40 and anti-CD86. Biotinylated mAbs were detected using
streptavidin-PE-Cy5. The cells were analyzed using a flow
cytometer EPICS ELITE (Beckman Coulter, CA), and WinMDI
for analysis software. BMDCs (5.06105) from MyD882/2 and
TRIF2/2 mice were stimulated with LPS or LPS-liposomes
(100 ng/mL) for 48 h, and stained with APC-Cy7-conjugated
anti-CD11c, PE-conjugated anti-CD40, and PE-conjugated anti-
CD86. The cells were analyzed using a flow cytometer FACS
Canto II (BD Biosciences), and Flowjo for analysis software.
Preparation of Mice Splenocytes
WT, IL-12p352/2, and IFN-a/bR2/2 mice were immunized
with OVA and LPS, or LPS-OVA-liposomes (10 mg each per mouse,
i.v.). After 1 week, spleens were removed, and splenic single-cell
suspensions were prepared [22,23]. Splenocytes from immunized
mice (56105) were incubated with OVA (1 mg/mL) for 72 h and
IFN-c and IL-4 levels were determined by ELISA. The splenocytes
were incubated in RPMI-1640 medium supplemented with 10%
FCS, 100 U/mL penicillin, 100 mg/mL streptomycin, 2 mM L-
glutamine, and 5610–5 M 2-mercaptoethanol.
Figure 2. LPS-liposomes induce IRF-3 activation but not NFkB
activation in the early phase. BMDCs (16106) from WT mice were
stimulated with LPS (100 ng/mL) or LPS-liposomes (100 ng/mL) for 0–
120 min. The cells were then lysed and the extracts were immuno-
blotted with the indicated antibodies. Data are average of three
independent experiments and band intensity was quantified with
Image J 1.45. The values represent means 6 S.E.M *P,0.05.
doi:10.1371/journal.pone.0068671.g002
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OVA-specific Antibody Determination
WT, IL-12p352/2, and IFN-a/bR2/2 mice were immunized
with OVA and LPS, or LPS-OVA-liposomes (10 mg each per
mouse, i.v.) and boosted after 2weeks. After a further 2 weeks, sera
were harvested and poured into an OVA-coated ELISA-plate, and
incubated overnight. Following washes with PBS containing
0.05% Tween-20, the wells were treated with AP-conjugated-
anti-mouse IgG1 or HRP-conjugated-anti-mouse IgG2c for 2 h.
Following washes, enzyme reaction was performed using p-
nitrophenyl phosphate or TMB as a substrate. Absorbance at
405 nm (with a reference at 540 nm) was measured using a Bio-
Rad Model 550 Microplate Reader, as described previously [24].
OVA-specific IgG was measured by ELISA using mouse anti-
OVA IgG antibody assay kit (Chondrex).
Statistical Analysis
The paired Student’s t test was used to compare paired groups.
Analysis of variance (ANOVA) was used for multi-group analysis.
P values,0.05 were considered significant.
Results
LPS-liposomes Induce IFN-b Production but not
Inflammatory Cytokines in BMDCs
First, we examined the production of cytokines and chemokines,
which are induced via the MyD88-dependent and TRIF-
dependent pathways. MyD88-dependent cytokines such as TNF-
a, IL-6, and IL-12 were highly produced by BMDCs in response
to LPS stimulation. By contrast, LPS-liposomes did not induce
Figure 3. LPS-liposomes induce co-stimulatory molecules in DCs as efficiently as LPS without inducing excessive production of
TNF-a. (A) WT mice were intravenously treated with LPS (10 mg per mouse) or LPS-liposomes (10 mg per mouse). At 6 h after treatment, splenocytes
were harvested and the expression of MHC-II, CD40, CD80, and CD86 on CD11c+ splenic DCs was analyzed by flow cytometry. Splenic DCs from PBS
treated mice were overlaid as control (open histograms). Percentage (%) are average of three independent experiments. n=3 animals per group. The
values represent means 6 S.E.M *P,0.05. (B) WT mice were intravenously treated with LPS or LPS-liposomes (10 mg per mouse). At 1.5 h after
treatment, sera were harvested and the level of TNF-a in the sera was determined by ELISA. Data are averages of three independent experiments.
n= 5 animals per group. The values represent means 6 S.E.M *P,0.05 (LPS vs. LPS-liposomes).
doi:10.1371/journal.pone.0068671.g003
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these inflammatory cytokines. The production of RANTES, a
TRIF-dependent chemokine, was induced by both LPS and LPS-
liposomes (Fig. 1A). Furthermore, the production of IFN-b, a
TRIF-dependent cytokine, was significantly up-regulated by LPS-
liposome stimulation compared with LPS (Fig. 1B), and the
expression of IFN-b mRNA was also highly induced by LPS-
liposome stimulation (Fig. 1C). Additionally, the production of IL-
12 was completely inhibited in MyD882/2 BMDCs by LPS, and
the production of IFN-b was significantly inhibited in TRIF2/2
BMDCs by LPS and LPS-liposomes (Fig. S1). These results
suggest that LPS-liposomes activate only the TRIF-dependent
pathway.
LPS-liposomes Induce IRF-3 Activation but not NFkB
Activation in the Early Phase
It has been reported that the activation of NFkB in the early
phase is induced by MyD88-dependent signaling, and the
activation of IRF-3 and NFkB in the late phase is induced by
TRIF-dependent signaling [9]. We next examined IRF-3 activa-
tion by detecting its phosphorylation, and NFkB activation by
detecting the degradation of IkBa which inhibits NFkB activation.
As shown in Figure 2A, phosphorylation of IRF-3 was induced by
both LPS and LPS-liposomes in BMDCs. In the case of IkBa,
early phase degradation was significantly detected in response to
LPS, and late phase degradation was significantly stronger in
response to LPS-liposome stimulation (Fig. 2B). These results also
support that LPS-liposomes activate only the TRIF-dependent
pathway.
LPS-liposomes Induce Co-stimulatory Molecules in DCs
as Efficiently as LPS without Inducing Excessive
Production of TNF-a
MHC-class II and co-stimulatory molecules such as CD40,
CD80, and CD86 are important to stimulate naı¨ve T cells to
differentiate into effector T helper cells. LPS has been shown to
induces the expression of co-stimulatory molecules in MyD882/2
DCs, suggesting that the TRIF-dependent pathway plays a critical
role in the induction of adaptive immunity [25]. In fact, TRIF2/
2BMDCs did not induce the expression of CD40 and CD86 by
LPS and LPS-liposomes compared with MyD882/2BMDCs (Fig.
S2). Therefore, we next examined the expression of co-stimulatory
molecules in response to LPS and LPS-liposomes in vivo. WT mice
were intravenously treated with LPS or LPS-liposomes, and
splenic DCs were analyzed using a flow cytometer. As expected,
LPS-liposomes induced the expression of MHC-class II, CD40,
Figure 4. LPS-liposomes enhance Th1- mediated antibody
responses. WT mice were immunized with LPS+OVA, OVA-liposomes,
or LPS-OVA-liposomes (10 mg each per mouse, i.v.) and boosted after 2
weeks. After a further 2 weeks, sera were harvested and OVA-specific
IgG, IgG1, and IgG2c levels were determined by ELISA. Data are
averages of three independent experiments. n= 5 animals per group.
The values represent means 6 S.E.M *P,0.05.
doi:10.1371/journal.pone.0068671.g004
Figure 5. Critical role of type-I IFN in LPS-liposome–induced
Th1-immune responses. WT, IL-12p352/2 (A), and IFN-a/bR2/2 mice
(B) were immunized with LPS plus OVA or LPS-OVA-liposomes (10 mg
each per mouse, i.v.). After 1 week, the spleens were removed and the
splenocytes (56105) were incubated with OVA (1 mg/mL) for 72 h, and
the levels of IFN-c and IL-4 were determined by ELISA. Data are
averages of three independent experiments. n= 3 animals per group.
The values represent means 6 S.E.M *P,0.05.
doi:10.1371/journal.pone.0068671.g005
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CD80, and CD86 as efficiently as LPS (Fig. 3A). Furthermore, the
treatment of LPS-liposomes did not induce the excessive
production of TNF-a in vivo, compared with LPS (Fig. 3B).
LPS-liposomes Enhance Th1-mediated Antibody
Responses
Next, we prepared OVA-encapsulating LPS-liposomes (LPS-
OVA-liposomes) to examine the induction of antigen-specific
immune responses. WT mice were immunized with LPS plus
OVA or LPS-OVA-liposomes and boosted after 2 weeks. After a
further 2 weeks, sera were harvested and OVA-specific antibodies
were examined by ELISA. As shown in Figure 4A, the production
of OVA-specific total IgG was enhanced when LPS was added
with OVA. LPS-OVA-liposomes elicited more effective produc-
tion of OVA-specific total IgG. Surprisingly, LPS-OVA-liposomes
significantly enhanced the production of OVA-specific IgG2c,
which are a Th1-mediated immune response (Fig. 4B). On the
other hand, the production of OVA-specific IgG1, which is a Th2-
mediated immune response, was slightly decreased in response to
LPS-OVA-liposome treatment compared with the OVA plus LPS
treatment (Fig. 4B).
Critical Role of Type-I IFN in LPS-liposome–induced Th1-
immune Responses
LPS-liposomes activate only the TRIF-dependent pathway but
not the MyD88-dependent pathway. Indeed, LPS-liposomes
induced type-I IFN but not IL-12 (Fig. 1A). It is well established
that IL-12 is important for the differentiation of naı¨ve T cells into
Th1 cells [13]. Therefore, we next examined the induction of
antigen-specific Th1-immune response by LPS plus OVA and
LPS-OVA-liposomes in IL-122/2 mice. Mice were immunized
with LPS plus OVA or LPS-OVA-liposomes. After 1 week,
splenocytes from immunized mice were incubated with OVA for
72 h and IFN-c and IL-4 levels were determined by ELISA. The
production of IFN-c, a Th1-mediated immune response, and the
production of IL-4, a Th2-mediated immune response, by LPS-
OVA-liposomes were not altered in IL-12p352/2 mice compared
with WT mice (Fig. 5A). On the other hand, the production of
IFN-c by LPS plus OVA was significantly decreased in IL-
12p352/2 mice (Fig. 5A). These results suggest that LPS-OVA-
liposomes induce antigen-specific Th1-immune responses inde-
pendent of IL-12. Therefore, we next focused on type-I IFN,
which is induced by LPS-liposomes via the TRIF-dependent
pathway. As shown in Figure 5B, IFN-c production was
completely inhibited in IFN-a/bR2/2 mice, strongly suggesting
that the Th1-immune responses induced by LPS-liposomes
depend on the induction of type-I IFN.
Antigen-specific IgG2c Production by LPS-liposomes
Depends on Type-I IFN
Finally, we examined the production of OVA-specific IgG2c, a
Th1-mediated immune response, by LPS-OVA-liposomes in IL-
12p352/2 and IFN-a/bR2/2 mice. The production of OVA-
specific total IgG was significantly decreased in IFN-a/bR2/2
mice (Fig. 6A). As expected, the production of OVA-specific
IgG2c was also significantly decreased in IFN-a/bR2/2 mice but
not in IL-12p352/2 mice, whereas the production of OVA-
specific IgG1 showed any change (Fig. 6B). These results also
support that the Th1-immune responses induced by LPS-
liposomes depend on type-I IFN but not IL-12.
Figure 6. Antigen-specific IgG2c production by LPS-liposomes
depends on type-I IFN.WT, IL-12p352/2, and IFN-a/bR2/2mice were
immunized with LPS plus OVA or LPS-OVA-liposomes (10 mg each per
mouse, i.v.), and boosted after 2 weeks. After a further 2 weeks, sera
were harvested and OVA-specific IgG, IgG1, and IgG2c levels were
determined by ELISA. Data are averages of three independent
experiments. n=5 animals per group. The values represent means 6
S.E.M *P,0.05.
doi:10.1371/journal.pone.0068671.g006
Figure 7. Model of the induction of Th1-immune responses by
LPS-liposomes. Unlike cell surface LPS, intracellular delivery of LPS by
liposomes does not induce inflammatory cytokine production, but
induces type-I IFN. IL-12 was thought to be required for Th1-immunity
induced by LPS. However, LPS-liposomes showed the critical role of
type-I IFN in the induction of Th1-immunity.
doi:10.1371/journal.pone.0068671.g007
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Discussion
To develop effective and safe immune adjuvants, it is important
to generate strong and long immune responses without inducing
unnecessary inflammation. Aluminum hydroxide is currently the
major human vaccine adjuvant approved. Although it is effective
in generating antibody responses, it requires repeated administra-
tion and tends to generate anti-parasitic Th2-immune responses,
rather than anti-viral and anti-bacterial Th1-immune responses
[26]. Recently, TLR ligands have been considered as candidate
for immune adjuvants, given their ability to induce strong Th1-
immune responses. However, these strong immune responses also
induce unnecessary inflammation, which are sometimes fatal.
Thus, it is very difficult to develop effective and safe immune
adjuvants.
LPS can induce strong Th1-immune responses, but also induces
unnecessary inflammations, which are induced via the MyD88-
dependent pathway. In the present study, we newly prepared LPS-
liposomes to deliver LPS into endosomes via endocytosis [18].
LPS-liposomes initiate only TRIF-dependent signaling via cla-
thrin-mediated endocytosis, and do not induce the production of
TNF-a and IL-6 but induce RANTES production in peritoneal
macrophages [18]. In fact, LPS-liposomes also initiate only TRIF-
dependent signaling in DCs which is essential for inducing
adaptive immune responses (Figs. 1, 2, S1, S2). It is reported that
the TRIF-dependent pathway is important for the induction of
adaptive immune responses [15,16]. As expected, like LPS, LPS-
liposomes induced the expression of MHC-class II and co-
stimulatory molecules such as CD40, CD80, and CD86, mediated
by the TRIF-dependent pathway (Fig. 3A). Additionally, the
treatment of LPS-liposomes did not induce the excessive
production of TNF-a in vivo, compared with LPS (Fig. 3B). These
results strongly suggest that LPS-liposomes activate only the
TRIF-dependent pathway without inducing unnecessary inflam-
mations via the MyD88-dependent pathway. The activation of
transcription factors further supports that LPS-liposomes are
TRIF-biased immune adjuvants (Fig. 2).
A recent study reported that LPS derivatives, such as MPLA,
can be used as vaccine adjuvants with low toxicity [17]. These LPS
derivatives are called TRIF-biased TLR4 agonists, and immuni-
zation with these agonists tends to activate the TRIF-dependent
pathway rather than the MyD88-dependent pathway. This study
also supports our observations that TRIF-biased immune adju-
vants could serve as safe immune adjuvants. MPLA is a safe
adjuvant, however, its ability to induce immune responses is
weaker than that of LPS [17]. It has also been reported that
MPLA can induce Th1-immune responses, but IFN-c treatment is
necessary and IL-12 production from DCs was also important
[27]. Hence, the new method of inducing Th1-immune responses,
without using MyD88-dependent pathway is needed.
LPS-liposomes induce effective antibody responses and Th1-
mediated antibody responses compared with LPS (Fig. 4).
Surprisingly, LPS-liposomes induced Th1-immune responses
independent of IL-12 (Figs. 5, 6). We discovered that type-I
IFN, but not IL-12, plays a critical role in the induction of Th1-
immune responses by LPS-liposomes (Fig. 7). This new mecha-
nism may aid the development of new vaccines against tumors and
infections, given that type-I IFN elicits anti-tumor and anti-viral
effects besides the induction of Th1-immune responses [28–30].
In conclusion, LPS-liposomes can effectively induce Th1-
immune responses without inducing unnecessary inflammation,
and may be useful as an immune adjuvant to induce protective
immunity (Fig. 7).
Supporting Information
Figure S1 LPS and LPS-liposomes induce IFN-b produc-
tion through the TRIF-dependent pathway in BMDCs.
MyD882/2 and TRIF2/2 BMDCs (1.06105) were stimulated
with LPS (100 ng/mL) or LPS-liposomes (100 ng/mL) for 9 h
(IFN-b) or 24 h (IL-12p40). Cytokine levels were determined by
ELISA. Data are average of two independent experiments. The
values represent means 6 S.E.M *P,0.05 (MyD882/2 vs.
TRIF2/2).
(TIF)
Figure S2 LPS and LPS-liposomes induce co-stimulato-
ry molecules through the TRIF-dependent pathway in
BMDCs. MyD882/2 and TRIF2/2 BMDCs (5.06105) were
stimulated with LPS or LPS-liposomes (100 ng/mL) for 48 h, and
the expression of CD40 and CD86 on CD11c+ BMDCs were
analyzed by flow cytometry. PBS treated BMDCs were overlaid as
control (black lines). Percentage (%) are average of three
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